Universe Financial Statements From 2010 to 2026

UPC Stock  USD 4.36  0.06  1.36%   
Universe Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Universe Pharmaceuticals' valuation are provided below:
Gross Profit
5.9 M
Profit Margin
(0.50)
Market Capitalization
2.5 M
Enterprise Value Revenue
0.0174
Revenue
19.3 M
We have found one hundred twenty available fundamental trend indicators for Universe Pharmaceuticals, which can be analyzed and compared to other ratios and to its competition. Investors should ensure to double-check all of Universe Pharmaceuticals' current performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road.

Universe Pharmaceuticals Total Revenue

25.38 Million

Check Universe Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Universe Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 516.7 K or Interest Expense of 185.5 K, as well as many indicators such as Price To Sales Ratio of 9.0E-4, Dividend Yield of 0.0765 or PTB Ratio of 3.0E-4. Universe financial statements analysis is a perfect complement when working with Universe Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Universe Stock
Check out the analysis of Universe Pharmaceuticals Correlation against competitors.
For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.

Universe Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets54.3 M79.7 M42.7 M
Slightly volatile
Short and Long Term Debt Total11.2 M10.6 M4.7 M
Slightly volatile
Other Current Liabilities2.7 M1.4 M6.3 M
Slightly volatile
Total Current Liabilities14.2 M15.2 M15.4 M
Slightly volatile
Total Stockholder Equity39.8 M64.5 M27.1 M
Slightly volatile
Net Tangible Assets32.4 M53.2 M25.8 M
Slightly volatile
Property Plant And Equipment Net12.1 M16.9 MM
Slightly volatile
Current Deferred Revenue34.8 K36.6 K441.4 K
Slightly volatile
Accounts Payable3.7 M1.9 M3.1 M
Pretty Stable
Cash40.6 M38.6 M13.2 M
Slightly volatile
Non Current Assets Total14.2 M18.1 M10.5 M
Slightly volatile
Other Assets15.6 M14.9 M5.7 M
Slightly volatile
Cash And Short Term Investments40.6 M38.6 M15.8 M
Slightly volatile
Net Receivables12.8 M15.2 M10.2 M
Slightly volatile
Common Stock Total Equity40 K45 K49.1 K
Slightly volatile
Common Stock Shares Outstanding3.8 KK7.4 K
Pretty Stable
Liabilities And Stockholders Equity51.4 M79.7 M42.6 M
Slightly volatile
Inventory2.5 MM5.1 M
Slightly volatile
Other Current Assets3.6 M5.3 MM
Slightly volatile
Other Stockholder Equity76.1 M72.5 M23.5 M
Slightly volatile
Total Liabilities14.5 M15.2 M15.5 M
Slightly volatile
Net Invested Capital45.1 M75.2 M31.4 M
Slightly volatile
Long Term Investments571.1 K632.1 K706.5 K
Slightly volatile
Property Plant And Equipment Gross15.6 M24.8 M11.1 M
Slightly volatile
Short and Long Term Debt11.2 M10.6 M4.5 M
Slightly volatile
Total Current Assets40 M61.6 M32.1 M
Slightly volatile
Accumulated Other Comprehensive Income535.2 K563.4 K2.3 M
Slightly volatile
Capital Stock7.7 M7.3 M1.3 M
Slightly volatile
Net Working Capital25.9 M46.5 M16.8 M
Slightly volatile
Short Term Debt11.2 M10.6 M4.7 M
Slightly volatile
Intangible Assets216.4 K341.3 K201 K
Slightly volatile
Common Stock7.7 M7.3 M1.7 M
Slightly volatile
Property Plant Equipment3.7 M3.8 M4.6 M
Slightly volatile
Non Currrent Assets Other30.7 K32.3 K1.7 M
Slightly volatile
Long Term Debt1.7 M1.9 M2.1 M
Slightly volatile

Universe Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization516.7 K595 K475.7 K
Slightly volatile
Interest Expense185.5 K266.8 K173.9 K
Slightly volatile
Selling General Administrative3.4 M4.8 M2.2 M
Slightly volatile
Selling And Marketing Expenses5.8 M4.4 M3.7 M
Slightly volatile
Total Revenue25.4 M16.1 M29.1 M
Pretty Stable
Gross Profit11.1 M5.7 M13 M
Slightly volatile
Other Operating Expenses31.6 M23.9 M24.1 M
Slightly volatile
Research Development733.9 K772.5 K1.8 M
Slightly volatile
Cost Of Revenue14.3 M10.4 M16.1 M
Very volatile
Total Operating Expenses14.5 M10.6 M9.2 M
Slightly volatile
Reconciled Depreciation518.9 K595 K473.9 K
Slightly volatile
Income Tax Expense518.7 K546 K1.6 M
Slightly volatile

Universe Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow35.6 M33.9 M11.4 M
Slightly volatile
Depreciation518.9 K595 K473.9 K
Slightly volatile
Capital Expenditures296.8 K312.5 K958.1 K
Pretty Stable
End Period Cash Flow40.6 M38.6 M13.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.0E-49.0E-42.0975
Slightly volatile
Dividend Yield0.07650.140.0932
Slightly volatile
PTB Ratio3.0E-43.0E-45.6723
Slightly volatile
Days Sales Outstanding123243134
Slightly volatile
Book Value Per Share15.3 K14.5 K5.8 K
Slightly volatile
Average Payables4.5 M3.8 M4.1 M
Pretty Stable
Capex To Depreciation0.730.772.1386
Pretty Stable
PB Ratio3.0E-43.0E-45.6723
Slightly volatile
Inventory Turnover5.724.744.7479
Slightly volatile
Days Of Inventory On Hand73.1879.65121
Slightly volatile
Payables Turnover6.457.965.7242
Pretty Stable
Sales General And Administrative To Revenue0.220.210.0744
Slightly volatile
Average Inventory3.5 M2.3 M3.9 M
Slightly volatile
Research And Ddevelopement To Revenue0.03220.03390.0558
Slightly volatile
Capex To Revenue0.02120.02240.0241
Pretty Stable
Cash Per Share9.1 K8.7 K3.1 K
Slightly volatile
Payout Ratio1.011.911.2339
Slightly volatile
Days Payables Outstanding54.7547.4667.4536
Pretty Stable
Intangibles To Total Assets0.00530.00490.0055
Slightly volatile
Current Ratio2.333.662.2114
Slightly volatile
Tangible Book Value Per Share15.2 K14.4 K5.7 K
Slightly volatile
Receivables Turnover1.481.563.073
Slightly volatile
Shareholders Equity Per Share15.3 K14.5 K5.8 K
Slightly volatile
Debt To Equity0.170.190.2055
Slightly volatile
Capex Per Share109115188
Pretty Stable
Average Receivables9.1 M12.9 M9.7 M
Slightly volatile
Revenue Per Share6.3 K5.9 K5.4 K
Slightly volatile
Interest Debt Per Share2.6 K2.5 K962
Slightly volatile
Debt To Assets0.080.120.0978
Pretty Stable
Graham Number22 K20.9 K13.7 K
Slightly volatile
Operating Cycle176305253
Slightly volatile
Price Book Value Ratio3.0E-43.0E-45.6723
Slightly volatile
Days Of Payables Outstanding54.7547.4667.4536
Pretty Stable
Dividend Payout Ratio1.011.911.2339
Slightly volatile
Ebt Per Ebit0.851.131.0218
Slightly volatile
Company Equity Multiplier1.681.422.0985
Slightly volatile
Long Term Debt To Capitalization0.03590.04040.0441
Slightly volatile
Total Debt To Capitalization0.140.160.1674
Slightly volatile
Debt Equity Ratio0.170.190.2055
Slightly volatile
Quick Ratio2.123.511.8883
Slightly volatile
Net Income Per E B T0.780.970.9005
Slightly volatile
Cash Ratio2.412.290.8691
Slightly volatile
Cash Conversion Cycle270257194
Very volatile
Days Of Inventory Outstanding73.1879.65121
Slightly volatile
Days Of Sales Outstanding123243134
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio2.011.231.4521
Pretty Stable
Price To Book Ratio3.0E-43.0E-45.6723
Slightly volatile
Fixed Asset Turnover1.331.44.284
Slightly volatile
Debt Ratio0.080.120.0978
Pretty Stable
Price Sales Ratio9.0E-49.0E-42.0975
Slightly volatile
Asset Turnover0.280.30.8349
Slightly volatile
Gross Profit Margin0.460.410.4414
Slightly volatile
Price Fair Value3.0E-43.0E-45.6723
Slightly volatile

Universe Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap16 K16.8 K735.5 K
Slightly volatile

Universe Fundamental Market Drivers

Universe Upcoming Events

9th of February 2024
Upcoming Quarterly Report
View
30th of September 2023
Next Fiscal Quarter End
View

About Universe Pharmaceuticals Financial Statements

Universe Pharmaceuticals stakeholders use historical fundamental indicators, such as Universe Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Universe Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Universe Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Universe Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Universe Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue36.6 K34.8 K
Total Revenue16.1 M25.4 M
Cost Of Revenue10.4 M14.3 M
Sales General And Administrative To Revenue 0.21  0.22 
Research And Ddevelopement To Revenue 0.03  0.03 
Capex To Revenue 0.02  0.02 
Revenue Per Share5.9 K6.3 K
Ebit Per Revenue(0.19)(0.18)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Universe Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Universe Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Universe Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Universe Pharmaceuticals Stock:
Check out the analysis of Universe Pharmaceuticals Correlation against competitors.
For information on how to trade Universe Stock refer to our How to Trade Universe Stock guide.
You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Will Biotechnology sector continue expanding? Could Universe diversify its offerings? Factors like these will boost the valuation of Universe Pharmaceuticals. If investors know Universe will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Universe Pharmaceuticals data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth
(0.82)
Earnings Share
(8.06)
Revenue Per Share
104.406
Quarterly Revenue Growth
(0.29)
Return On Assets
(0.08)
The market value of Universe Pharmaceuticals is measured differently than its book value, which is the value of Universe that is recorded on the company's balance sheet. Investors also form their own opinion of Universe Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Universe Pharmaceuticals' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Universe Pharmaceuticals' market value can be influenced by many factors that don't directly affect Universe Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Universe Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Universe Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Universe Pharmaceuticals' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.